Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0T9LR
|
||||
| Former ID |
DNCL003801
|
||||
| Drug Name |
Liprotamase
|
||||
| Synonyms |
LY3031642
|
||||
| Indication | Cystic fibrosis [ICD9: 277; ICD10:E84] | Phase 3 | [1] | ||
| Company |
Lilly
|
||||
| Target and Pathway | |||||
| Target(s) | Pancreatic alpha-amylase | Target Info | Modulator | [2] | |
| Triacylglycerol lipase, pancreatic | Target Info | Modulator | [2] | ||
| Chymotrypsin | Target Info | Modulator | [2] | ||
| BioCyc Pathway | Triacylglycerol degradation | ||||
| Retinol biosynthesis | |||||
| KEGG Pathway | Glycerolipid metabolism | ||||
| Metabolic pathways | |||||
| Pancreatic secretion | |||||
| Fat digestion and absorption | |||||
| Vitamin digestion and absorption | |||||
| Reactome | Retinoid metabolism and transport | ||||
| WikiPathways | Visual phototransduction | ||||
| Lipid digestion, mobilization, and transport | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00500084) Phase III ALTU-135 CP Safety Trial. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of Anthera Pharmaceuticals. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.